Author(s):
Amisha R. Ghuge, Shashikant N. Dhole, Nilesh S. Kulkarni, Tejal B. Medankar
Email(s):
amisha.ghuge30@gmail.com
DOI:
10.52711/2231-5713.2025.00040 
Address:
Amisha R. Ghuge*, Shashikant N. Dhole, Nilesh S. Kulkarni, Tejal B. Medankar
Department of Pharmaceutics, PES Modern College of Pharmacy (for Ladies), Moshi, Pune - 412105, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2025
ABSTRACT:
Inflammatory Bowel Disease is chronic and debilitating disorder affects millions globally. It is a long-term condition marked by repeated episodes of inflammation in the digestive tract. Rectal suppositories are an effective treatment method for IBD, especially when the disease affects the lower colon and rectum. The article provides an overview of IBD, including its causes, progression and available treatments, with a particular emphasis on rectal suppositories as an alternative to oral medications. The benefits of rectal suppositories include the ability to avoid first-pass metabolism and deliver the medication directly to the site of inflammation. Rectal suppositories provide a practical and effective treatment for IBD patients, particularly those with mild to moderate disease activity and involvement of the distal colon. The review highlights the benefits and challenges of rectal suppositories in IBD treatment, including mesalamine, corticosteroids, and tacrolimus. The review also examines factors to consider in formulation, such as the type of base used in suppository and the preparation methods. Overall, rectal suppositories present a promising treatment strategy for IBD and ongoing research aims to improve their effectiveness while reducing systemic side effects. Further research is needed to optimize suppository design and delivery systems, ultimately enhancing therapeutic outcomes for IBD patients.
Cite this article:
Amisha R. Ghuge, Shashikant N. Dhole, Nilesh S. Kulkarni, Tejal B. Medankar. Rectal Suppositories for Treatment of Inflammatory Bowel Disease: A Review. Asian Journal of Pharmacy and Technology. 2025; 15(3):261-0. doi: 10.52711/2231-5713.2025.00040
Cite(Electronic):
Amisha R. Ghuge, Shashikant N. Dhole, Nilesh S. Kulkarni, Tejal B. Medankar. Rectal Suppositories for Treatment of Inflammatory Bowel Disease: A Review. Asian Journal of Pharmacy and Technology. 2025; 15(3):261-0. doi: 10.52711/2231-5713.2025.00040 Available on: https://ajptonline.com/AbstractView.aspx?PID=2025-15-3-8
REFERENCES:
1. Senior, N. Advances in Pharmaceutica l Sciences, Vol.4, Eds. H.S. Bean, A.H. Beckett and J.E. Carless, Academic Press Inc.1974:364.
2. Baviskar P, Bedse A, Sadique S, Kunde V, Jaiswal S. Drug delivery on rectal absorption: suppositories. Int J Pharm Sci Rev Res. 2013 Jul; 21(1): 70-76. available on http://www.globalresearchonline.net/
3. Ham AS, Buckheit Jr RW. Designing and developing suppository formulations for anti-HIV drug delivery. Therapeutic delivery. 2017 Aug 1; 8(9): 805-817.doi: 10.4155/tde-2017-0056
4. Yasmitha B, Pallavi A, Devaki D, Vasundhara A. A review on suppositories. GSC Biological and Pharmaceutical Sciences. 2023; 25(1): 186-192.doi: 10.30574/gscbps.2023.25.1.0429
5. Misbah Ul Haq M, Munaf Ur Razzak M, Arif Uddin M, Nazish A, Shahidulla SM. Rectal Drug Delivery System: An Overview. Clin Pharmacol Biopharm.2021 May; 10(5): 219. available on https://www.researchgate.net/publication/355172305_Rectal_Drug_Delivery_System_An_Overview
6. Hargoli S, Farid J, Azarmi SH, Ghanbarzadeh S, Zakeri-Milani P. Preparation and in vitro evaluation of naproxen suppositories. Indian Journal of Pharmaceutical Sciences. 2013 Mar; 75(2): 143.
7. Lebrat M, Bouattour Y, Gaudet C, Yessaad M, Jouannet M, Wasiak M, Dhifallah I, Beyssac E, Garrait G, Chennell P, Sautou V. Development and Stability of a New Formulation of Pentobarbital Suppositories for Paediatric Procedural Sedation. Pharmaceutics. 2023 Feb 24; 15(3): 755.doi: 10.3390/pharmaceutics15030755
8. Persaud S, Eid S, Swiderski N, Serris I, Cho H. Preparations of rectal suppositories containing artesunate. Pharmaceutics. 2020 Mar; 12(3). doi:10.3390/pharmaceutics12030222.
9. Akl MA, Ismael HR, Abd Allah FI, Kassem AA, Samy AM. Tolmetin sodium-loaded thermosensitive mucoadhesive liquid suppositories for rectal delivery; strategy to overcome oral delivery drawbacks. Drug Development and Industrial Pharmacy. 2019 Feb; 45(2): 252-264.doi: 10.1080/03639045.2018.1534858
10. Fakhar-ud-Din, Khan GM. Development and characterisation of levosulpiride-loaded suppositories with improved bioavailability in vivo. Pharmaceutical Development and Technology. 2019 Jan 2; 24(1): 63-69.doi: 10.1080/10837450.2017.1419256
11. Katata-Seru L, Ojo BM, Okubanjo O, Soremekun R, Aremu OS. Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories. Heliyon. 2020 May 1; 6(5). doi: 10.1016/j.heliyon. 2020.e03890
12. Saleem MA, Taher M, Sanaullah S, Najmuddin M, Ali J, Humaira S, Roshan S. Formulation and evaluation of tramadol hydrochloride rectal suppositories. Indian Journal of Pharmaceutical Sciences. 2008 Sep;70(5):640-644.
13. Hammouda YE, Kasim NA, Nada AH. Formulation and in vitro evaluation of verapamil HCl suppositories. International Journal of Pharmaceutics. 1993 Jan 15;89(2): 111-118.doi: 10.1016/0378-5173(93)90111-R
14. Samy EM, Hassan MA, Tous SS, Rhodes CT. Improvement of availability of allopurinol from pharmaceutical dosage forms I-suppositories. European Journal of Pharmaceutics and Biopharmaceutics. 2000 Mar 1; 49(2): 119-127.doi:10.1016/S0939-6411(99)00079-X
15. Berko S, Regdon Jr G, Ducza E, Falkay G, Erős I. In vitro and in vivo study in rats of rectal suppositories containing furosemide. European Journal of Pharmaceutics and Biopharmaceutics. 2002 May 1;53(3): 311-315.doi: 10.1016/S0939-6411(02)00005-X
16. Buyukkoroglu G, Senel B, Yenilmez E. Vaginal suppositories with siRNA and paclitaxel-incorporated solid lipid nanoparticles for cervical cancer: Preparation and in vitro evaluation. RNA Interference and Cancer Therapy: Methods and Protocols. 2019 May:303-328.
17. Shivhare SC, Shivhare UD, Srivastav P, Malviya KG. Formulation of Clotrimazole vaginal suppository containing Lacto bacillus spores. Asian Journal of Pharmacy and Technology. 2013;3(1):5-8.
18. KD Tripathi. Drugs for Constipation and Diarrhoea. Essentials of Medical Pharmacology. Edited by M. Tripathi, London.2019; 8th ed: pp. 721-738.
19. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe?. World Journal of Gastroenterology: WJG. 2011 Feb 2;17(5): 557-566.doi: :10.3748/wjg. v17.i5.557
20. Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. Journal of Immunology Research. 2019;2019(1): 7247238.doi: 10.1155/2019/7247238
21. Park SC, Jeen YT. Genetic studies of inflammatory bowel disease-focusing on Asian patients. Cells. 2019 May 1;8(5): 404.doi: 10.3390/cells8050404
22. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clinical Practice Gastroenterology & hepatology. 2006 Jul; 3(7): 390-407.
23. Krishna VP, Vinit CJ, Neelam P. Pharmacology of combined mesalazine and rifaximin therapy to inflammatory bowel disease. Asian Journal of Pharmaceutical Research. 2016;6(1):45-50.
24. O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best practice & research Clinical Gastroenterology. 2006 Jan 1; 20(3): 561-73.doi: 10.1016/j.bpg.2006.03.001
25. Lakatos PL. Environmental factors affecting inflammatory bowel disease: have we made progress. Digestive Diseases. 2009 Sep 24; 27(3): 215-25.doi: 10.1159/000228553
26. Sutaria R, Mok ZH. Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease. Pharmaceutical Science Advances. 2023 Oct 16: 100014.doi: 10.1016/j.pscia.2023.100014
27. Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Disease-a-month. 2019 Dec 1;65(12): 100851.doi: 10.1016/j.disamonth.2019.02.004
28. Chambrun GP, Tassy B, Kollen L, Dufour G, Valats JC, Bismuth M, Funakoshi N, Panaro F, Blanc P. Refractory ulcerative proctitis: How to treat it?. Best Practice & Research Clinical Gastroenterology. 2018 Feb 1; 32: 49-57.doi: 10.1016/j.bpg.2018.05.009
29. Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet. 2012 Nov 3;380(9853): 1590-605.doi: http: 10.1016/S0140-6736(12)60026-9
30. Imbrizi M, Magro F, Coy CS. Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years. Pharmaceuticals. 2023 Sep 8;16(9): 1272.doi: 10.3390/ph16091272
31. Krishna KV, Patro VJ. Articulation and evaluation of extended-release beads using a sulfasalazine drug. Asian Journal of Pharmacy and Technology. 2023; 13(1): 25-8. doi: 10.52711/2231-5713.2023.00005
32. Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Frontiers in Medicine. 2021 Dec 20;8: 765474.doi: 10.3389/fmed.2021.765474
33. Kengar MD, Howal RS, Aundhakar DB, Nikam AV, Hasabe PS. Physico-chemical properties of solid drugs: a review. Asian Journal of Pharmacy and Technology. 2019; 9(1): 53-9. doi:10.5958/2231-5713.2019.00010.2
34. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life. 2019 Apr; 12(2): 113.doi: 10.25122/jml-2018-0075
35. Yash Sinha, Kuldeep Singh Patel, Vaishali Rathi, Jagdish Chandra Rathi, Archana Singh. Comparative Assessment of Multi brand and Generic Methylprednisolone tablets marketed in India. Asian J. Pharm. Tech. 2020; 10(1): 1-6.
36. Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L, Chaturvedi R, Peek RM, Wilson KT, Polk DB. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. The Journal of Clinical Investigation. 2011 Jun 1;121(6): 2242-2253.
37. Lokhande S, More S, Raje V. A systematic study of probiotics-an update review. Asian Journal of Pharmacy and Technology. 2018; 8(3): 149-57. doi:10.5958/2231-5713.2018.00024.7
38. Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes. 2017 May 4;8(3): 238-252.doi: 10.1080/19490976.2017.1290757
39. Ferrante M, Pouillon L, Mañosa M, Savarino E, Allez M, Kapizioni C, Arebi N, Carvello M, Myrelid P, De Vries AC. Results of the Eighth Scientific Workshop of ECCO: prevention and treatment of postoperative recurrence in patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis. Journal of Crohn's and Colitis. 2023 Nov 1;17(11): 1707-22.doi:10.1093/ecco-jcc/jjad053
40. Zheng B, Wang L, Yi Y, Yin J, Liang A. Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease. Asian Journal of Pharmaceutical Sciences. 2024 Jul 14: 100943.doi: 10.1016/j.ajps.2024.100943
41. Srujana K, Hemalatha B, Padmalatha K. A review on colon targeted drug delivery system. Asian Journal of Pharmacy and Technology. 2023; 13(1): 57-64. doi:10.52711/2231-5713.2023.00012
42. Pachpute T, Dwivedi J, Shelke T, Jeyabalan G. Formulation and evaluation of mesalamine nanosphere tablet. Journal of Drug Delivery and Therapeutics. 2019 Dec 5;9(4-s): 1045-53.doi: 10.22270/jddt. v9i4-s.3763
43. Alkilani AZ, Omar S, Nasereddin J, Hamed R, Obeidat R. Design of colon-targeted drug delivery of dexamethasone: Formulation and in vitro characterization of solid dispersions. Heliyon. 2024 Jul 30;10(14). doi: 10.1016/j.heliyon. 2024.e34212
44. Varshosaz J, Ahmadi F, Emami J, Tavakoli N, Minaiyan M, Mahzouni P, Dorkoosh F. Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in rat. International Journal of Preventive Medicine. 2010;1(2):115-123.
45. Dawadi S, Pradhananga E, Chaudhary K, Rojee K, Sidgel A, Khanal S. Formulation and In-vitro Evaluation of Mesalamine Rectal Suppositories for Ulcerative Colitis. North American Acad Res. 2021; 4(5): 275-86.doi: 10.5281/zenod o.4866973
46. Haznar-Garbacz D, Garbacz G, Weitschies W. Development of oral foams for topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology. 2019 Apr 1; 50(2019): 287-92.doi: 10.1016/j.jddst.2019.01.022
47. Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, Narayan J, Zierden H, Betageri K, Musmanno O, Wiegand H. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018 Dec 1; 185: 97-105.doi: 10.1016/j.biomaterials.2018.09.005.
48. Ramadass SK, Perumal S, Jabaris SL, Madhan B. Preparation and evaluation of mesalamine collagen in situ rectal gel: A novel therapeutic approach for treating ulcerative colitis. European Journal of Pharmaceutical Sciences. 2013 Jan 23;48(1-2): 104-110.doi: 10.1016/j.ejps.2012.10.015
49. Gharat JS, Dalvi YV. Compressive review on hydrogel. Asian Journal of Pharmacy and Technology. 2018; 8(3): 172-81. doi:10.5958/2231-5713.2018.00028.4
50. Dubey P, Begum RF, Chitra V, Mrinalini R, Gunasekaran H, Sumithra M. Formulation, standardization, and preclinical evaluation of polyherbal suspension against inflammatory bowel disease. J Nat Remedies. 2022 Jul 30;22(3): 412-423.doi: 10.18311/jnr/2022/29781
51. Paun JS, Tank HM. Nanosuspension: An emerging trend for bioavailability enhancement of poorly soluble drugs. Asian Journal of pharmacy and Technology. 2012;2(4):157-68.
52. Nath B, Nath LK. Design, development and optimization of oral colon targeted drug delivery system of azathioprine using biodegradable polymers. Pharmaceutical Development and Technology. 2013 Oct 1;18(5): 1131-1139.doi: 10.3109/10837450.2012.727002
53. Havaldar VD, Yadav AV, Dias RJ, Mali KK, Ghorpade VS, Salunkhe NH. Rectal suppository as an effective alternative for oral administration. Research Journal of Pharmacy and Technology. 2015; 8(6): 759-766.doi: 10.5958/0974-360X.2015.00122.5
54. Si Y, Shao L, Gao S, Wen H. Suppository treatment in ulcerative proctitis. European Journal of Inflammation. 2021 Jun; 19: 1-9.
55. Williams CN. Role of rectal formulations: suppositories. Scandinavian Journal of Gastroenterology. 1990 Jan 1; 25(172): 60-62.
56. Jaeger SU, Klag T, Hoeger K, Klumpp S, Escher M, Malek N, Stange E, Wehkamp J. Tacrolimus suppositories in therapy-resistant ulcerative proctitis. Inflammatory Intestinal Diseases. 2019 Feb 8;3(3): 116-24.doi: 10.1159/000493979
57. Morgan L, Smith R, Weekes H, Parkes M, Lee JC. Tacrolimus suppositories: a safe and effective treatment for treatment-refractory proctitis. 14th ECCO. 2019.
58. Lie MR, Kreijne JE, Dijkstra G, Lowenberg M, van Assche G, West RL, van Noord D, van der Meulen-de AE, Oldenburg B, Zaal RJ, Hansen BE. No superiority of tacrolimus suppositories vs beclomethasone suppositories in a randomized trial of patients with refractory ulcerative proctitis. Clinical Gastroenterology and Hepatology. 2020 Jul 1;18(8): 1777-1784.doi: 10.1016/j.cgh.2019.09.049
59. Leon LA, Herbert LI and Joseph KA. Suppositories. The Theory and Practice of Industrial Pharmacy.1990;3rd ed: pp.564-588.
60. Melnyk G, Yarnykh T, Herasymova I. Analytical review of the modern range of suppository bases. Syst. Rev. Pharm. 2020 Apr 1;11: 503-508.doi: 10.5530/srp.2019.2.04
61. Kalmar E, Ueno K, Forgo P, Szakonyi G, Dombi G. Novel sample preparation method for surfactant containing suppositories: effect of micelle formation on drug recovery. Journal of Pharmaceutical and Biomedical Analysis. 2013 Sep 1;83: 149-56. doi: 10.1016/j.jpba.2013.04.039
62. Thakur B, Pandit V, Ashawat MS, Kumar P. Natural and synthetic polymers for colon targeted drug delivery. Asian Journal of Pharmacy and Technology. 2016; 6(1): 35-44. doi: 10.5958/2231-5713.2016.00006.4
63. Nedelcu A, Mosteanu O, Pop T, Mocan T, Mocan L. Recent advances in nanoparticle-mediated treatment of inflammatory bowel diseases. Applied Sciences. 2021 Jan 5;11(1): 438.doi: 10.3390/app11010438
64. Khayatan D, Lemberg DA, Day AS. The Role of Topical Tacrolimus in the Management of Inflammatory Bowel Disease: A Comprehensive Review. Journal of Clinical Medicine. 2024 Sep 18; 13(18): 5518.doi: 10.3390/jcm13185518